164 related articles for article (PubMed ID: 30529460)
1. Reduced-Toxicity Myeloablative Conditioning Consisting of Fludarabine/Busulfan/Low-Dose Total Body Irradiation/Granulocyte Colony-Stimulating Factor-Combined Cytarabine in Single Cord Blood Transplantation for Elderly Patients with Nonremission Myeloid Malignancies.
Konuma T; Kato S; Isobe M; Mizusawa M; Oiwa-Monna M; Takahashi S; Tojo A
Biol Blood Marrow Transplant; 2019 Apr; 25(4):764-770. PubMed ID: 30529460
[TBL] [Abstract][Full Text] [Related]
2. Feasibility of an intensified myeloablative conditioning regimen consisting of busulfan, fludarabine, cytarabine, and total body irradiation before single cord blood transplantation in elderly patients.
Kawakita T; Hirano T; Inoue Y; Irie Y; Sugitani H; Kubota A; Watanabe M; Ueno M; Mitsui N; Yamaguchi S; Inoue Y; Sakai T; Harada N; Matsuoka M; Hidaka M
Int J Hematol; 2021 Jul; 114(1):85-93. PubMed ID: 33740219
[TBL] [Abstract][Full Text] [Related]
3. Single-unit cord blood transplantation after granulocyte colony-stimulating factor-combined myeloablative conditioning for myeloid malignancies not in remission.
Konuma T; Kato S; Ooi J; Oiwa-Monna M; Ebihara Y; Mochizuki S; Yuji K; Ohno N; Kawamata T; Jo N; Yokoyama K; Uchimaru K; Asano S; Tojo A; Takahashi S
Biol Blood Marrow Transplant; 2014 Mar; 20(3):396-401. PubMed ID: 24333750
[TBL] [Abstract][Full Text] [Related]
4. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcomes following the addition of granulocyte colony-stimulating factor-combined high-dose cytarabine to total body irradiation and cyclophosphamide conditioning in single-unit cord blood transplantation for myeloid malignancies.
Konuma T; Ooi J; Nagayama H; Tomonari A; Tsukada N; Kato S; Kawakita T; Isobe M; Monna-Oiwa M; Tojo A; Iseki T; Takahashi S
Ann Hematol; 2022 Jan; 101(1):177-189. PubMed ID: 34591162
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
[TBL] [Abstract][Full Text] [Related]
7. A Novel Reduced-Toxicity Myeloablative Conditioning Regimen Using Full-Dose Busulfan, Fludarabine, and Melphalan for Single Cord Blood Transplantation Provides Durable Engraftment and Remission in Nonremission Myeloid Malignancies.
Yamamoto H; Uchida N; Yuasa M; Kageyama K; Ota H; Kaji D; Nishida A; Ishiwata K; Takagi S; Tsuji M; Asano-Mori Y; Yamamoto G; Izutsu K; Masuoka K; Wake A; Yoneyama A; Makino S; Taniguchi S
Biol Blood Marrow Transplant; 2016 Oct; 22(10):1844-1850. PubMed ID: 27345142
[TBL] [Abstract][Full Text] [Related]
8. A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis.
Gooptu M; Kim HT; Ho VT; Alyea EP; Koreth J; Armand P; Ritz J; Nikiforow S; Glotzbecker BE; Nageshwar P; Soiffer RJ; Antin JH; Cutler CS
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1733-1740. PubMed ID: 29555313
[TBL] [Abstract][Full Text] [Related]
9. Cord blood transplantation for acute myelogenous leukemia using a conditioning regimen consisting of granulocyte colony-stimulating factor-combined high-dose cytarabine, fludarabine, and total body irradiation.
Tomonari A; Takahashi S; Ooi J; Nakaoka T; Takasugi K; Uchiyama M; Tsukada N; Konuma T; Iseki T; Tojo A; Asano S
Eur J Haematol; 2006 Jul; 77(1):46-50. PubMed ID: 16573743
[TBL] [Abstract][Full Text] [Related]
10. [Comparison of intensified myeloablative conditioning regime without antithymocytic globulin (ATG) with myeloablative conditioning regime for single-unit unrelated umbilical cord blood transplantation in hematological malignancies].
Sun ZM; Liu HL; Wu Y; Geng LQ; Zheng CC; Tang BL; Zhu XY; Tong J; Wang XB; Ding KY; Wan X; Zhang L; Yao W; Zhang XH; Han YS; Yang HZ; Liu X; Zhu WW; Wu JS; Wang ZY
Zhonghua Yi Xue Za Zhi; 2016 Jul; 96(28):2214-9. PubMed ID: 27480651
[TBL] [Abstract][Full Text] [Related]
11. Fludarabine, cytarabine, granulocyte colony-stimulating factor and melphalan (FALG with L-PAM) as a reduced toxicity conditioning regimen in children with acute leukemia.
Kato K; Yoshida N; Matsumoto K; Matsuyama T
Pediatr Blood Cancer; 2014 Apr; 61(4):712-6. PubMed ID: 24376191
[TBL] [Abstract][Full Text] [Related]
12. Fludarabine and busulfan plus low-dose TBI as reduced intensity conditioning in older patients undergoing allogeneic hematopoietic cell transplant for myeloid malignancies.
Khalil MMI; Messner HA; Lipton JH; Kim DD; Viswabandya A; Thyagu S; Deotare U; Michelis FV
Ann Hematol; 2018 Oct; 97(10):1975-1985. PubMed ID: 29947975
[TBL] [Abstract][Full Text] [Related]
13. Adult Umbilical Cord Blood Transplantation Using Myeloablative Thiotepa, Total Body Irradiation, and Fludarabine Conditioning.
Anand S; Thomas S; Corbet K; Gasparetto C; Long GD; Lopez R; Morris AK; Rizzieri DA; Sullivan KM; Sung AD; Sarantopoulos S; Chao NJ; Horwitz ME
Biol Blood Marrow Transplant; 2017 Nov; 23(11):1949-1954. PubMed ID: 28729147
[TBL] [Abstract][Full Text] [Related]
14. Transplant Conditioning with Treosulfan/Fludarabine with or without Total Body Irradiation: A Randomized Phase II Trial in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia.
Deeg HJ; Stevens EA; Salit RB; Ermoian RP; Fang M; Gyurkocza B; Sorror ML; Fatobene G; Baumgart J; Burroughs LM; Delaney C; Doney K; Egan DN; Flowers MED; Milano F; Radich JP; Scott BL; Sickle EJ; Wood BL; Yeung C; Storer BE
Biol Blood Marrow Transplant; 2018 May; 24(5):956-963. PubMed ID: 29274396
[TBL] [Abstract][Full Text] [Related]
15. Survival Advantage and Comparable Toxicity in Reduced-Toxicity Treosulfan-Based versus Reduced-Intensity Busulfan-Based Conditioning Regimen in Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients after Allogeneic Hematopoietic Cell Transplantation.
Sakellari I; Mallouri D; Gavriilaki E; Batsis I; Kaliou M; Constantinou V; Papalexandri A; Lalayanni C; Vadikolia C; Athanasiadou A; Yannaki E; Sotiropoulos D; Smias C; Anagnostopoulos A
Biol Blood Marrow Transplant; 2017 Mar; 23(3):445-451. PubMed ID: 27914967
[TBL] [Abstract][Full Text] [Related]
16. A New Conditioning Regimen Can Significantly Promote Post-Transplant Immune Reconstitution and Improve the Outcome of Umbilical Cord Blood Transplantation for Patients.
Yu ZP; Ding JH; Sun AN; Chen BA; Ge Z; Wu DP
Stem Cells Dev; 2019 Oct; 28(20):1376-1383. PubMed ID: 31464164
[TBL] [Abstract][Full Text] [Related]
17. Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis.
Le Bourgeois A; Mohr C; Guillaume T; Delaunay J; Malard F; Loirat M; Peterlin P; Blin N; Dubruille V; Mahe B; Gastinne T; Le Gouill S; Moreau P; Mohty M; Planche L; Lode L; Bene MC; Chevallier P
Biol Blood Marrow Transplant; 2013 Jun; 19(6):934-9. PubMed ID: 23523970
[TBL] [Abstract][Full Text] [Related]
18. Total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine as a conditioning regimen in allogeneic hematopoietic stem cell transplantation for advanced myelodysplastic syndrome: a single-institute experience.
Mori T; Aisa Y; Yokoyama A; Nakazato T; Yamazaki R; Shimizu T; Mihara A; Kato J; Watanabe R; Takayama N; Ikeda Y; Okamoto S
Bone Marrow Transplant; 2007 Feb; 39(4):217-21. PubMed ID: 17220902
[TBL] [Abstract][Full Text] [Related]
19. A Chemotherapy-Only Regimen of Busulfan, Melphalan, and Fludarabine, and Rabbit Antithymocyte Globulin Followed by Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplantations for the Treatment of Myeloid Malignancies.
Spitzer B; Jakubowski AA; Papadopoulos EB; Fuller K; Hilden PD; Young JW; Barker JN; Koehne G; Perales MA; Hsu KC; van den Brink MR; Kernan NA; Prockop SE; Scaradavou A; Castro-Malaspina H; O'Reilly RJ; Boulad F
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2088-2095. PubMed ID: 28711727
[TBL] [Abstract][Full Text] [Related]
20. Unrelated-donor bone marrow transplantation with a conditioning regimen including fludarabine, busulfan, and 4 Gy total body irradiation.
Onishi Y; Mori S; Kusumoto S; Sugimoto K; Akahane D; Morita-Hoshi Y; Kim SW; Fukuda T; Heike Y; Tanosaki R; Tobinai K; Takaue Y
Int J Hematol; 2007 Apr; 85(3):256-63. PubMed ID: 17483064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
